Literature DB >> 26935512

Resistant Hypertension.

Adrian Doroszko1, Agnieszka Janus2, Ewa Szahidewicz-Krupska2, Grzegorz Mazur2, Arkadiusz Derkacz1.   

Abstract

Resistant hypertension is a severe medical condition which is estimated to appear in 9-18% of hypertensive patients. Due to higher cardiovascular risk, this disorder requires special diagnosis and treatment. The heterogeneous etiology, risk factors and comorbidities of resistant hypertension stand in need of sophisticated evaluation to confirm the diagnosis and select the best therapeutic options, which should consider lifestyle modifications as well as pharmacological and interventional treatment. After having excluded pseudohypertension, inappropriate blood pressure measurement and control as well as the white coat effect, suspicion of resistant hypertension requires an analysis of drugs which the hypertensive patient is treated with. According to one definition - ineffective treatment with 3 or more antihypertensive drugs including diuretics makes it possible to diagnose resistant hypertension. A multidrug therapy including angiotensin - converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers, diuretics, long-acting calcium channel blockers and mineralocorticoid receptor antagonists has been demonstrated to be effective in resistant hypertension treatment. Nevertheless, optional, innovative therapies, e.g. a renal denervation or baroreflex activation, may create a novel pathway of blood pressure lowering procedures. The right diagnosis of this disease needs to eliminate the secondary causes of resistant hypertension e.g. obstructive sleep apnea, atherosclerosis and renal or hormonal disorders. This paper briefly summarizes the identification of the causes of resistant hypertension and therapeutic strategies, which may contribute to the proper diagnosis and an improvement of the long term management of resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26935512     DOI: 10.17219/acem/58998

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  17 in total

Review 1.  Multidisciplinary Approach in the Treatment of Resistant Hypertension.

Authors:  S A Potthoff; O Vonend
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

2.  MiR-20b-5p contributes to the dysfunction of vascular smooth muscle cells by targeting MAGI3 in hypertension.

Authors:  Minzhi Xu; Ting Yu
Journal:  J Mol Histol       Date:  2022-01-05       Impact factor: 2.611

3.  Hypertension, C Reactive Protein and Metabolic Profile: What is the Scenario in Patients Undergoing Arteriography?

Authors:  Ricardo Jose Tofano; Sandra Maria Barbalho; Marcelo Dib Bechara; Karina Quesada; Claudemir Gregorio Mendes; Marie Oshiiwa
Journal:  J Clin Diagn Res       Date:  2017-08-01

4.  Formononetin induces vasorelaxation in rat thoracic aorta via regulation of the PI3K/PTEN/Akt signaling pathway.

Authors:  Teng Li; Yuanyuan Zhong; Tao Tang; Jiekun Luo; Hanjin Cui; Rong Fan; Yang Wang; Dongsheng Wang
Journal:  Drug Des Devel Ther       Date:  2018-11-01       Impact factor: 4.162

5.  Obstructive sleep apnea, hypertension, resistant hypertension and cardiovascular disease.

Authors:  Shazia Jehan; Ferdinand Zizi; Seithikurippu R Pandi-Perumal; Samy I McFarlane; Girardin Jean-Louis; Alyson K Myers
Journal:  Sleep Med Disord       Date:  2020-11-23

6.  Atypical Case of Minoxidil-Induced Generalized Anasarca and Pleuropericardial Effusion.

Authors:  Wahab A Gbadamosi; Jacqueline Melvin; Marvin Lopez
Journal:  Cureus       Date:  2021-06-03

7.  Frequency and predictors of compliance among patients taking antihypertensive medicines.

Authors:  Ekta Mutneja; Rakesh Yadav; Aparajit Ballav Dey; Pooja Gupta
Journal:  Indian Heart J       Date:  2020-04-13

8.  Effects of renal denervation on blood-pressure response to hemorrhagic shock in spontaneously hypertensive rats.

Authors:  Xiao-Na Cai; Chao-Yi Wang; Yuan Cai; Fang Peng
Journal:  Chin J Traumatol       Date:  2018-10-01

Review 9.  Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice.

Authors:  Jakub Gawrys; Karolina Gawrys; Ewa Szahidewicz-Krupska; Arkadiusz Derkacz; Jakub Mochol; Adrian Doroszko
Journal:  Biomed Res Int       Date:  2018-10-02       Impact factor: 3.411

Review 10.  Fighting Oxidative Stress with Sulfur: Hydrogen Sulfide in the Renal and Cardiovascular Systems.

Authors:  Joshua J Scammahorn; Isabel T N Nguyen; Eelke M Bos; Harry Van Goor; Jaap A Joles
Journal:  Antioxidants (Basel)       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.